CMN Weekly (14 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 14, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Arbor Biotechnologies
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Primary Hyperoxaluria, undisclosed liver diseases
Genome editing tool: CRISPR-Cas13d, multiple novel CRISPR variants
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://arbor.bio/
Pipeline: https://arbor.bio/our-approach
Gene editing partnerships: Vertex Pharmaceuticals, Vor Biopharma
Arbor Biotechnologies is a CRISPR-focused company that develops novel Cas variants for enhanced precision and efficacy. The company's lead programme is being developed for primary hyperoxaluria. The company is co-founded by CRISPR pioneer Feng Zhang and has established multiple collaborations, including but not limited to Vertex Pharmaceuticals and Vor Biopharma.
